[go: up one dir, main page]

MX2019010572A - Composicion que comprende avelumab. - Google Patents

Composicion que comprende avelumab.

Info

Publication number
MX2019010572A
MX2019010572A MX2019010572A MX2019010572A MX2019010572A MX 2019010572 A MX2019010572 A MX 2019010572A MX 2019010572 A MX2019010572 A MX 2019010572A MX 2019010572 A MX2019010572 A MX 2019010572A MX 2019010572 A MX2019010572 A MX 2019010572A
Authority
MX
Mexico
Prior art keywords
avelumab
composition
disorder
compositions
detrimental
Prior art date
Application number
MX2019010572A
Other languages
English (en)
Inventor
Grazia Terlizzese Maria
Cavaliere Francesca
R Pezzotti Anna
De Rossi Elio
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2019010572A publication Critical patent/MX2019010572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a composiciones de anticuerpo de avelumab con un elevado nivel de desamidacion, asi como a metodos para la utilizacion de tales composiciones para tratar un trastorno, por ejemplo, un trastorno en el cual es danina la interaccion entre PD-1 y PD-L1.
MX2019010572A 2017-03-06 2018-03-05 Composicion que comprende avelumab. MX2019010572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17159470.8A EP3372615A1 (en) 2017-03-06 2017-03-06 Composition comprising avelumab
PCT/EP2018/055379 WO2018162430A1 (en) 2017-03-06 2018-03-05 Composition comprising avelumab

Publications (1)

Publication Number Publication Date
MX2019010572A true MX2019010572A (es) 2020-01-14

Family

ID=58264431

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010572A MX2019010572A (es) 2017-03-06 2018-03-05 Composicion que comprende avelumab.

Country Status (15)

Country Link
US (1) US20200031933A1 (es)
EP (2) EP3372615A1 (es)
JP (1) JP2020509063A (es)
KR (1) KR20190126103A (es)
CN (1) CN110691791A (es)
AR (1) AR111165A1 (es)
AU (1) AU2018232556A1 (es)
BR (1) BR112019018384A2 (es)
CA (1) CA3054833A1 (es)
IL (1) IL269120A (es)
MX (1) MX2019010572A (es)
RU (1) RU2019130333A (es)
SG (1) SG11201907892VA (es)
TW (1) TW201832782A (es)
WO (1) WO2018162430A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101888321B1 (ko) * 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
WO2016128912A1 (en) * 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
SG10201810615VA (en) 2015-02-26 2019-01-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
WO2016181348A1 (en) 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
WO2017046746A1 (en) * 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
PL3402503T3 (pl) * 2016-01-13 2021-04-19 Acerta Pharma B.V. Kombinacje terapeutyczne antyfolianu oraz inhibitora btk

Also Published As

Publication number Publication date
CN110691791A (zh) 2020-01-14
CA3054833A1 (en) 2018-09-13
KR20190126103A (ko) 2019-11-08
EP3372615A1 (en) 2018-09-12
JP2020509063A (ja) 2020-03-26
RU2019130333A (ru) 2021-04-07
BR112019018384A2 (pt) 2020-04-07
AU2018232556A1 (en) 2019-09-19
EP3592773A1 (en) 2020-01-15
US20200031933A1 (en) 2020-01-30
SG11201907892VA (en) 2019-09-27
WO2018162430A1 (en) 2018-09-13
TW201832782A (zh) 2018-09-16
IL269120A (en) 2019-11-28
AR111165A1 (es) 2019-06-12

Similar Documents

Publication Publication Date Title
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
ZA201802331B (en) Stable inoculant compositions and methods for producing same
MY203971A (en) Anti-lag-3 antibodies and compositions
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
MX2019007020A (es) Anticuerpos il-11.
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MX2018003472A (es) Moduladores de la expresion de kras.
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
PH12021552158A1 (en) Antibodies to icos
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2017001290A (es) Composicion para el tratamiento de telas que comprende una nanoemulsion de polimero de aminosiloxano.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
EP4385521A3 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2019000088A (es) Composiciones y metodos para detectar y tratar la diabetes.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
PH12020550023A1 (en) Compositions for treating stress-related disorders
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF